Prospective Italian real‐world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports.

Prospective Italian real-world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports Current asthma guidelines inform about evidence-based approaches to optimize patient outcomes. Notably, the severity of asthma experienced by patients in both studies was very similar, and additionally patients had similar annual exacerbation rates (3.48 vs. 4.09 exacerbations/year) and similar hospitalization rates (0.44/year vs. 0.39/year). [Extracted from the article]